www.ThePharmaJournal.com

The Pharma Innovation

ISSN (E): 2277- 7695
ISSN (P): 2349-8242
NAAS Rating: 5.03
TPI 2020; 9(6): 494-499

www.thepharmajournal.com
Received: 22-04-2020
Accepted: 24-05-2020

Y Phalguna
Bharat Institute of Technology, Mangalpally (V), Ibrahimpatnam (M), R.R-District, Telangana, India

Swetha Pothula
Research scientist, Granules Pharmaceuticals Inc., Concorde pkwy, Chantilly, VA, USA

Ravinder Kumar Sarepalli
Research scientist, Granules Pharmaceuticals Inc., Concorde pkwy, Chantilly, VA, USA

Bobby Murala
Bharat Institute of Technology, Mangalpally (V), Ibrahimpatnam (M), R.R-District, Telangana, India

Corresponding Author:
Y Phalguna
Bharat Institute of Technology, Mangalpally (V), Ibrahimpatnam (M), R.R-District, Telangana, India

Design, characterization and *In vitro* evaluation of polymeric nanoparticles containing decitabine

Y Phalguna, Swetha Pothula, Ravinder Kumar Sarepalli and Bobby Murala

Abstract
The point of this investigation is to figure the Decitabine stacked nanoparticles Guar gum and PEG for anticancer treatment, so as to improve the bioavailability and to diminish the portion recurrence. Plans of Decitabine stacked nanoparticles were set up by Nano precipitation strategy. Fourier transmission infrared spectroscopy considers demonstrated no compound association among medication and polymer. Scanning electron microscope instrument indicated nanoparticles having a discrete circular structure without conglomeration the normal molecule size was discovered 141±132 nm. % yield was appeared in the middle of 54.29 ± 0.02 to 61.42 ± 0.02 and Entrapment effectiveness was appeared in the middle of 48.32 ± 0.02 to 74.62 ±0.02. The zeta potential was seen as - 4.2mV. *In vitro* discharge examines were performed by utilizing Franz diffusion cell apparatus. The FN9 detailing indicated sedate arrival of 94.16% for a time of 12hrs.

Keywords: Decetabine, nano precipitation, FTIR, franz diffusion, Zeta potential

1. Introduction
Leukaemia is a clonal illness of hematopoietic immature microorganisms, and it is a harmful tumour that truly undermines human lives [1]. Intense myeloid leukaemia (AML) is a typical sort of leukaemia that happens in the two kids and grown-ups. It is portrayed by a quickly detonating populace of unusual white platelets that aggregate and lead to diminished creation of typical platelets. Nano scale plan has huge low molecule size that may prompt sensational changes in the pharmacokinetics of medications with poor solvency or porousness issues. As an outcome, Nano definition permits progressively detached dissemination and infiltration of medication around 15-250 times more prominent than that of miniaturized scale particles through the natural films [2]. The accomplishment of oral chemotherapy can significantly change the clinical act of chemotherapy and fundamentally improve the personal satisfaction of the disease patients. The oral course is by a wide margin the most favoured course because of higher patient consistence, simplicity of organization, less expensive expenses, and so forth [3]. Leukaemia speaks to a lot of harmful illnesses described by an anomalous collection of platelets, commonly WBCs (white platelets). Based on the movement of the illness and hematopoietic heredities included, leukaemia's arranged as intense versus incessant and myeloid versus lymphoid [4]. Scientists have been attempting to improve the conveyance of decitabine on various frameworks, for example, Nano gels [5], nanostructured lipid bearers [6, 7], liposomes [8] and designed erythrocyte (Erythrocyte-Magneto-Hem agglutinin Virosomes, EMHVs) tranquilize conveyance framework [9]. At all occasions, the significant undertakings for analysts are to improve the capture of the medication in the conveyance framework and to upgrade the bioavailability. Here, the Nano particulate conveyance frameworks expect to improve the dependability of medication, its length of helpful activity, and bioavailability, while limiting its debasement, digestion and cell efflux [10, 11]. Decitabine (DEC) or 5-aza-2′-deoxycytidine, is a particular cytosine simple with a property to repress DNMTs. It synthetically turns around quality quieting of tumour silencer qualities, and has become an energizing methodology for disease treatment [12]. It's endorsed by the US FDA for use as a immunotherapeutic operator against haematological malignancies [13]. It has effectively demonstrated remedial activity in patients with myelodysplastic disorder (MDS) in clinical preliminaries at higher stages. DEC is likewise dynamic in both intense and constant leukaemia's too [14].

2. Materials and methods

Decitabine was procured from Micro labs, India. Guar gum, Ethanol, Acetone, and PEG was purchased from SD fine Ltd., Hyderabad. All other chemicals used in research work were of analytical grade.

2.1. Nano precipitation method

Nanoparticles containing Decitabine were readied utilizing Nano precipitation technique. Nanoparticles were set up by utilizing diverse drug to polymer proportion. Drug was dissolved in 10 ml of distilled water, at that point dissolvable (Acetone 5 mL) was included into this arrangement. A dissolvable was required so as to make the internal stage progressively homogeneous. At that point polymer and Polyethylene glycol were broken down in 10 ml of chloroform, and this arrangement was added to the medication answer for structure dispersion. The dispersion was added to 10 ml of aqueous ethanol arrangement (70%). Following 5 minutes of blending, the natural solvents were expelled by dissipation at 35°C under ordinary pressure, nanoparticles were isolated by utilizing cooling rotator (10000 rpm for 20 min), supernatant were evacuated and nanoparticles washed with water and dried at room temperature and put away in desiccator.

Table 1: Formulation of Decitabine Nanoparticles

S. No.	Formulation code	Drug (mg)	Polymer (mg)	PEG (ml)	Acetone (ml)
1	FN1	50 mg	50	10	5
2	FN2	50 mg	100	15	5
3	FN3	50 mg	150	20	5
4	FN4	50 mg	50	25	5
5	FN5	50 mg	100	30	5
6	FN6	50 mg	150	35	5
7	FN7	50 mg	50	40	5
8	FN8	50 mg	100	45	5
9	FN9	50 mg	150	50	5

2.2. Fourier transform infra-red (FT-IR) spectroscopy analysis

IR ghostly investigation of unadulterated medication Decitabine and polymers was completed and perception was made whether changes happened in substance constitution of medication subsequent to joining it with the polymers. The examples were squashed with KBr to get pellets by applying pressure on 600 Kg/cm2 and examined with the IR instrument (Shimadzu, 8400 Series, Tokyo, Japan) from 400-4000cm-1 [15].

2.3. Percentage Yield

The percentage yield of different formulations was determined by weighing the nanoparticles after drying. The percentage yield was calculated as follows.

$$\text{Percentage yield} = \frac{\text{Total weight of nanoparticles}}{\text{Total weight of drug \& polymer}} \times 100$$

2.4. Drug Entrapment Efficiency

50 mg of nanoparticle from all batches is definitely weight.20 ml phosphate buffer is added to. After this, after proper dilution, the total amount of drug was found in UV-spectrophotometric method at 240nm.

$$\text{Entrapment Efficacy} = \frac{\text{Mass of drug in nanoparticles}}{\text{Mass of drug in formulation}} \times 100$$

2.5. Surface morphology

Nanoparticle's particle size is a very important feature. Surface appearance and the size of nanoparticles are distributed by the scanning electron microscope (SEM). The size and surface of the thumbnails are tested by scanning the ultrasonic microscope.

2.6. Particle size analysis

The Size distribution of the Nanoparticle's was determined using the particle size analyser (Beckman Coulter, Delsa Nano C, Brea, USA) equipped with a dry accessory system. Sample was diluted with water and temperature maintained at 25°C [16].

2.7. Zeta potential analysis

The zeta potential was measured using the (Beckman Coulter Delsa Nano C, Brea, USA. Instrument). The sample was diluted with double distilled water and taken in the cuvettes and temperature maintained at 25°C [17].

2.8. *In Vitro* drug release study

In vitro sedate discharge investigations of Decetabine Nano particles were completed for all definitions utilizing Franz dispersion cell device. Franz dissemination cell contains two compartments one is giver compartment another acceptor compartment. The Nanoparticle's are set in contributor compartment by utilizing with 6.8 phosphate buffer about 10ml. The clear is kept as 6.8 phosphate support. The *in vitro* reads did for about 12hours. 1ml of the example of defined decitabine Nano particles aliquot was pulled back at foreordained interims and equivalent volume of disintegration medium was supplanted to keep up sink condition. The required dilutions were made with buffer and the solution was analysed for the drug content spectrophotometric ally at 240 nm against suitable blank.

3. Results and discussion

FTIR spectra revealed characteristic absorption peaks of pure glimepiride at C-H Bending 1713.96 cm^{-1}, C=O Stretching 1240.03 $cm^{-1,}$ C=C Stretching 2314.91 cm^{-1}, O-H Stretching 3014.04 cm^{-1}. These data suggested that there were no considerable changes in IR peaks.



Fig 1: FTIR spectra of the Decetabine drug



Fig 2: FTIR spectra of drug and polymer

Percentage yield was shown in between 54.29 ± 0.02 to 61.42 ± 0.02 and Entrapment efficiency was shown in between 48.32 ± 0.02 to 74.62 ±0.02. The results are shown in Table no.2.

Table 2: Results of Percentage yield and Entrapment efficiency

S. No.	Formulation code	Percentage yield	Entrapment efficiency
1	FN1	54.29 ± 0.02	48.32 ± 0.02
2	FN2	53.81±0.04	39.18 ± 0.03
3	FN3	53.09 ± 0.05	23.39 ± 0.05
4	FN4	52.32 ± 0.02	39.09 ± 0.05
5	FN5	51.8 ± 0.03	45.92±0.06
6	FN6	54.92 ± 0.04	56.43 ± 0.03
7	FN7	56.71 ± 0.05	64.13 ± 0.08
8	FN 8	60.13 + 0.04	70.83 ± 0.03
9	FN9	61.42 ± 0.02	74.62 ±0.02

SEM were used to determine the particle morphology and structure of the mesoporous materials. As shown in SEM images (Fig. 3), particles exhibit spherical shape.



Fig 3: Scanning electron micrographs of formulation FN9 with magnification 2000x

Particle size analysis was performed on the optimized formulation; optimization was based upon the drug release study, particle size analysis was performed in order to investigate whether the particle size is within the range. The maximum diameter of the particles is found to be 141±132 nm. (Fig.4)



Fig 4: Particle Size analysis of Formulation FN9

Zeta potential is used to determine the electrophoretic mobility of particles. The magnitude of the zeta potential gives an indication of the potential stability of the colloidal system. The zeta potential was found to be -4.2mV.(Fig 5).



Fig 5: Zeta potential of Formulation FN9

Table 3: *In vitro* drug release studies

Time in hrs.	FN1	FN2	FN3	FN4	FN5	FN6	FN7	FN8	FN9
1	13.42	11.47	10.42	10.0	9.22	8.47	12.67	11.47	7.87
2	21.65	18.38	17.97	17.96	15.69	17.62	20.36	18.38	14.11
3	27.64	26.50	24.24	24.54	21.78	25.58	28.13	26.50	20.25
4	33.57	32.56	31.53	30.49	27.34	32.4	36.06	32.56	26.48
5	40.55	38.05	38.47	36.72	33.33	38.79	45.34	38.0	32.79
6	46.28	44.79	44.35	42.43	39.64	43.98	54.50	44.79	38.58
7	53.40	51.64	50.43	49.18	46.18	48.24	60.89	51.64	44.80
8	60.19	58.87	57.41	56.48	53.40	54.65	64.13	58.87	50.51
9	67.04	65.95	63.44	63.42	60.11	59.24	68.64	65.95	58.39
10	74.34	72.29	70.72	70.20	66.59	64.76	72.66	72.29	64.29
11	80.91	78.83	76.01	76.60	73.20	69.56	77.86	78.83	70.74
12	98.55	97.60	96.02	97.91	96.48	95.15	98.10	97.60	94.16



Fig 6: Comparative drug release profiles of FN1- FN9

The drug release of prepared nanoparticles with different combination of polymers Guar gum and PEG of different ratios showed slower release when there was an increase in the concentration. It was also observed that drug entrapment and drug loading also affect the drug release from nanoparticles. The formulation FN1 showed 98.55% release of the drug for a period of 12hrs. The FN9 showed drug release of 94.16% for a period of 12hrs (Fig 6).

4. Conclusion

In the present study a satisfactory attempt was made to develop nanoparticles of Decitabine with improved bioavailability, efficient targeting, and improved the patient compliance. The optimized nanoparticle formulation FN9 could be employed to minimize the adverse effects of Decitabine.

5. References

1. Beran M. Intensive chemotherapy for patients with high-risk myelodysplastic syndrome. Int J Hematol. 2000; 72:139-150.
2. Dave VS, Gupta D, Yu M, Nguyen P, Varghese, Gupta S *et al*. Current and evolving approaches improving the oral permeability of BCS Class III or analogous molecules. Drug Dev. Ind Pharm. 2017; 43(2):177-89.
3. Yun Y, Cho YW, Park K. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Advanced drug delivery reviews. 2013; 65(6):822-832.
4. Huggins CB, Grand L, Ueda N. Specific induction of Erythroleukaemia and myelogenous leukemia in Sprague-Dawley rats. Proceedings of the National Academy of Sciences. 1982; 79(17):5411-5414.
5. Vijayaraghavalu S, Labhasetwar V. Efficacy of decitabine-loaded Nano gels in overcoming cancer drug resistance is mediated via sustained DNA methyl transferees 1 (DNMT1) depletion. Cancer letters. 2013; 331(1):122-129.
6. Neupane YR, Srivastava M, Ahmad N, Kumar N, Bhatnagar A, Kohli K *et al*. Lipid based Nano carrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and *in vivo* assessment. International journal of pharmaceutics, 2014, 477(1), 601-612.
7. Neupane YR, Srivastava M, Ahmad N, Soni K, Kohli K. Stability indicating RP-HPLC method for the estimation of Decitabine in bulk drug and lipid based Nanoparticles. Int J Pharm Sci Res. 2014; 7:294.
8. Lim SP, Kumar R, Akkamsetty Y, Wang W, Ho K, Neilsen PM. *et al*. Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine. BMC cancer. 2013; 13(1):113.
9. Naldi I, Taranta M, Gherardini L, Pelosi G, Viglione F, Grimaldi S *et al*. Novel epigenetic target therapy for prostate cancer: a preclinical study. PloS one. 2014; 9(5):98-101.
10. Li X, Xu Y, Chen G, Wei P, Ping Q. PLGA nanoparticles for the oral delivery of 5-Fluorouracil using high pressure homogenization-emulsification as the preparation method and *in vitro*/*in vivo* studies. Drug development and industrial pharmacy. 2008; 34(1):107-115.
11. Sarmento B, Ribeiro A, Veiga F, Ferreira D, Neufeld R. Oral bioavailability of insulin contained in polysaccharide nanoparticles. Bio macromolecules. 2007; 8(10):3054-3060.
12. Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Annals of Oncology. 2002; 13(11):1699-1716.
13. Issa JPJ Epigenetics in cancer: what's the future? Oncology. 2011; 25(3):220.
14. Oki Y, Aoki E, Issa JPJ. Decitabine-bedside to bench. Critical reviews in oncology/hematology. 2007; 61(2):140-152.
15. Zhang C, Ping Q, Shen J. Synthesis and characterization of water soluble o-succinyl-chitosan. European Polymer J. 2003; 39:1629-1634.
16. Donbrow M, Samuelov Y. Zero order drug delivery from double-layered porous films: Release rate profiles from ethyl cellulose, hydroxypropyl cellulose and polyethylene glycol mixtures. J Pharm Pharmacol. 1980; 32:463-470.
17. Sandri. Chitosan-associated SLN: *in vitro* and ex vivo Characterization of Cyclosporine A loaded ophthalmic systems. J of microencapsulation. 2010; 27:735-746.